special laboratory for biopharmaceuticals in animal cells

 

 Editor de Conteúdo ‭[1]‬

 
general objective of the unit

The Laboratory dedicates itself to the development of monoclonal antibodies in murine, humanized and human formats. The laboratory’s beginnings are related to its finding of technological routes related to the development of processes which led to the production of the monoclonal, anti-CD3 antibody. The antibody was used with the efficiency expected in the control of renal transplant rejection and is currently the target of humanization with the goal of expanding its range of therapeutic potential.  Cell lines for humanized antibodies in the treatment of cancer are developed with productivity and stability that is scalable. Moreover, there was implementation of the methodology for obtaining human antibodies from the specific capture of B lymphocytes of immunized people; development of cell lines for biosimilar monoclonal antibodies; generation of antibody variants through  phage display technology. Collaborations with pharmaceutical companies for the production of biosimilar monoclonal antibodies have recently been signed by the Ministry of Health as part of the Productive Development Partnerships (Parceiras de Desenvolvimento Produtivo, PDP) program.

 

The Laboratory still performs gene design, cloning and expression of recombinant antibodies, biochemical and functional characterization for the selection of clones, cultures in bioreactors, procedures development, purification and analytical assays.

 

 Editor de Conteúdo ‭[2]‬